z-logo
open-access-imgOpen Access
Unicellular Eukaryote as a Bio-cellular Model for Studying Effect Benzimidazole: Ultrastructural Analysis
Author(s) -
Karlen Hovnanyan
Publication year - 2021
Publication title -
open access journal of mycology and mycological sciences
Language(s) - English
Resource type - Journals
ISSN - 2689-7822
DOI - 10.23880/oajmms-16000132
Subject(s) - benzimidazole , eukaryote , ultrastructure , mechanism of action , biology , biochemistry , microbiology and biotechnology , chemistry , in vitro , botany , genome , organic chemistry , gene
The search for new derivatives of benzoimidazole with an active center that have a wide range of biological effects (antifungal, antiflammatory, antibacterial, antiviral, antitumor, antidiabetic, etc.) is the subject of modern pharmaceutical science. To determine the mechanism of action of benzoimidazole, a search is underway for more. We have previously carried out the Ultrastructural characterization of various prokaryotes and protists, as well as the mechanism of action of antibiotics and chemical preparations on them. From a series of heterocyclic drugs, a drug with a wide spectrum of action was chosen as derivatives of benzimidazole and a model of a free-living unicellular eukaryote Endameba moshkovskii with a vegetative and cystic form. The purpose of this work is the nature of the action of drugs of the benzimidazole series and in the ultrastructural visualization of the mechanism of action of benzimidazole using electron microscopic and electron-cytochemical methods on the model of polyxenic cultures of unicellular eukaryotes Entamoeba moshkovskii. We have established for the first time the excising effect of benzimidazole and the functional-ultrastructural mechanism of the action of benzimidazole on entameoba cells. As a result, the ultrastructural and functional morphology of benzimidazole action in the process of excysting entamoeba was established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here